Roche PD-L1+TIGIT combination fails in first-line treatment of stage III small cell lung cancer

• Facebook
• Twitter
• Reddit
• Google
• Tumblr
• LinkedIn
• Pinterest
• RSS Feed
• Link

Roche PD-L1+TIGIT combination fails in first-line treatment of stage III small cell lung cancer

• New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
• Is the new COVID Omicron variant BA.4.6 more contagious?
• How long can the patient live after heart stent surgery?
• First time: Systemic multi-organ recovery after death
• Where do the bacteria in the human gut come from?

Roche PD-L1+TIGIT combination fails in first-line treatment of stage III small cell lung cancer. 

On March 30, Roche announced that the phase III clinical trial (SKYSCRAPER-02) of tiragolumab + atezolizumab (TIGIT + PD-L1) in the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) did not reach progression-free survival (SKYSCRAPER-02). PFS) primary endpoint.

Roche said that phase III clinical trials of PD-L1+TIGIT combination therapy for non-small cell lung cancer, esophageal squamous cell carcinoma and other cancers will continue as planned.

SKYSCRAPER-02 is a randomized, double-blind, placebo-controlled, global Phase III study to compare tiragolumab plus atezolizumab, chemotherapy as first-line therapy with atezolizumab and chemotherapy in 490 ES- Efficacy and safety in SCLC patients. The primary endpoints were overall survival (OS) and progression-free survival (PFS).

Tiragolumab is a TIGIT monoclonal antibody that has been granted breakthrough therapy designation by the FDA. By binding to TIGIT, it can block the interaction of TIGIT with a poliovirus receptor (PVR, or CD155) protein that can inhibit the body’s immune response, potentially enhancing the body’s immune response.

Atezolizumab (trade name: Taishengqi) is a PD-L1 immune checkpoint inhibitor independently designed and developed by Roche, which can directly interact with the PD-L1 ligand protein expressed on tumor cells and tumor-infiltrating immune cells.

Binds to block the interaction of PD-L1 with PD-1 and B7.1 receptors on immune cells, effectively activating T cells to recognize and kill tumor cells. Currently, the product has been approved for multiple indications, including non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, triple negative breast cancer and urothelial cancer.

The combination of Tiragolumab and Tecentriq synergistically blocks TIGIT and PD-L1, activates T cells and enhances NK cell antitumor activity.

(source:internet, reference only)

Disclaimer of medicaltrend.org